New Tougher Law to Govern China’s Vaccine Industry Starting December

From newborn infants to adults studying overseas, the safety of vaccines has become a heated topic argued by the public. Some international students contend that a certain type of vaccines in their American insurance (aka 美国保险 疫苗) plans should be removed.

The price of International Student Health Insurance (aka 留学生 保险) Plan is not inexpensive, and the unnecessary immunization coverage adds their financial burdens. Moreover, the safety of injecting vaccine panics people. Hence, some voices rise up: is it necessary to include vaccine in OPT Insurance (aka opt 保险) Plans, J-1 Visa Insurance (aka j1 签证 保险) Plan, Travel Insurance recommended in America (aka 美国旅游保险推荐), and/or H-1B Insurance (aka h1b 保险) Plans.

According to a newly passed law on vaccine administration, said at a press conference Saturday, all vaccine products in China will be tracked and supervised throughout their product lifecycle officials.

The law will take effect on December 1. Experts say that the move could be a milestone in vaccine safety, while bringing back market confidence in the regulatory system.

Passed by China’s top legislature, the National People’s Congress, on Saturday, the law requires “strictest” management by setting up a supervision system over the entire process and tougher penalties for producing and selling fake or substandard vaccines.

The full product lifecycle within the e-tracking system includes vaccine production, distribution and vaccination, the press briefing said.

“The National Medical Products Administration (NMPA) is working with the National Health Commission to build a nationwide vaccine tracking platform for supervision and regulation of enterprises,” Yuan Lin, head of the drug supervision and management department under the administration, told the press conference.

Liu Junhai, a business law professor at Renmin University of China, told the Global Times that the tracking system is definitely an innovative move. “Once the platform is in place, each vaccine will be traceable under the product profile. It will take just one scan to trace the producer, quality check and distribution process. Thus, consumers will regain their confidence and regulation efficiency will be improved too,” Liu elaborated.